Alternative splicing as a biomarker and potential target for drug discovery

Alternative splicing is a key process of multi-exonic gene expression during pre-mRNA maturation. In this process, particular exons of a gene will be included within or excluded from the final matured mRNA, and the resulting transcripts generate diverse protein isoforms. Recent evidence demonstrates...

Full description

Saved in:
Bibliographic Details
Published inActa pharmacologica Sinica Vol. 36; no. 10; pp. 1212 - 1218
Main Authors Le, Kai-qin, Prabhakar, Bellur S, Hong, Wan-jin, Li, Liang-cheng
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.10.2015
Nature Publishing Group
Subjects
Alternative Splicing - drug effects
Animals
Biomedical and Life Sciences
Biomedicine
Diabetes Mellitus - drug therapy
Diabetes Mellitus - genetics
Drug Discovery - methods
Genetic Markers - genetics
Humans
Immunology
Internal Medicine
Medical Microbiology
Molecular Targeted Therapy - methods
Neoplasms - drug therapy
Neoplasms - genetics
Neurodegenerative Diseases - drug therapy
Neurodegenerative Diseases - genetics
Pharmacology/Toxicology
Review
RNA, Messenger - genetics
Vaccine
人类疾病
前体mRNA
基因表达
生物标志物
神经退行性疾病
药物发现
选择性剪接
靶点
neurodegenerative diseases
alternative splicing
drug discovery
mRNA
cancer
human diseases
biomarker
diabetes
Online AccessGet full text
ISSN1671-4083
1745-7254
1745-7254
DOI10.1038/aps.2015.43

Cover

More Information
Summary:Alternative splicing is a key process of multi-exonic gene expression during pre-mRNA maturation. In this process, particular exons of a gene will be included within or excluded from the final matured mRNA, and the resulting transcripts generate diverse protein isoforms. Recent evidence demonstrates that approximately 95% of human genes with multiple exons undergo alternative splicing during pre-mRNA maturation. Thus, alternative splicing plays a critical role in physiological processes and cell development programs, and.dysregulation of alternative splicing is highly associated with human diseases, such as cancer, diabetes and neurodegenerative diseases. In this review, we discuss the regulation of alternative splicing, examine the relationship between alternative splicing and human diseases, and describe several approaches that modify alternative splicing, which could aid in human disease diagnosis and therapy.
Bibliography:mRNA; alternative splicing; human diseases; cancer; diabetes; neurodegenerative diseases; biomarker; drug discovery
Alternative splicing is a key process of multi-exonic gene expression during pre-mRNA maturation. In this process, particular exons of a gene will be included within or excluded from the final matured mRNA, and the resulting transcripts generate diverse protein isoforms. Recent evidence demonstrates that approximately 95% of human genes with multiple exons undergo alternative splicing during pre-mRNA maturation. Thus, alternative splicing plays a critical role in physiological processes and cell development programs, and.dysregulation of alternative splicing is highly associated with human diseases, such as cancer, diabetes and neurodegenerative diseases. In this review, we discuss the regulation of alternative splicing, examine the relationship between alternative splicing and human diseases, and describe several approaches that modify alternative splicing, which could aid in human disease diagnosis and therapy.
31-1347/R
ObjectType-Article-1
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1671-4083
1745-7254
1745-7254
DOI:10.1038/aps.2015.43